Computational analysis of plasmepsin IV bound to an allophenylnorstatine inhibitor

FEBS Letters

Volumn 580, Issue 25, 2006, Pages 5910-5916

  Gutiérrez de Terán, Hugo ^a   Nervall, Martin ^a   Dunn, Ben M ^b   Clemente, Jose C ^b   Åqvist, Johan ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Enzyme inhibitors; Linear interaction energy method; Malaria; Plasmepsin

Indexed keywords

ALLOPHENYLNORSTATINE INHIBITOR; ANTIMALARIAL AGENT; PLASMEPSIN I; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CALCULATION; CONFORMATION; DATA ANALYSIS; DRUG BINDING; DRUG STRUCTURE; DRUG TARGETING; ENERGY TRANSFER; EXPERIMENTATION; METHODOLOGY; MOLECULAR DYNAMICS; NONHUMAN; PLASMODIUM MALARIAE; PRIORITY JOURNAL; PROTON TRANSPORT; SPECIES DIVERSITY;

ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; ASPARTIC ENDOPEPTIDASES; CATALYTIC DOMAIN; ELECTROSTATICS; HYDROGEN BONDING; MODELS, MOLECULAR; PHENYLBUTYRATES; PLASMODIUM FALCIPARUM; PROTEASE INHIBITORS; PROTEIN CONFORMATION; STATIC ELECTRICITY; THERMODYNAMICS;

HUMAN IMMUNODEFICIENCY VIRUS 1; PLASMODIUM FALCIPARUM; PLASMODIUM MALARIAE;

EID: 33750087338     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2006.09.057     Document Type: Article

References (42)

1. Ersmark K., Feierberg I., Bjelic S., Hulten J., Samuelsson B., Aqvist J., and Hallberg A. C-2-symmetric inhibitors of Plasmodium falciparum plasmepsin II: synthesis and theoretical predictions. Bioorg. Med. Chem. 11 (2003) 3723-3733
2. Ersmark K., Nervall M., Gutiérrez-de-Terán H., Hamelink E., Janka L.K., Clemente J.C., Dunn B.M., Gogoll A., Samuelsson B., Aqvist J., and Hallberg A. Macrocyclic inhibitors of the malarial aspartic proteases plasmepsin I, II, and IV. Bioorg. Med. Chem. 14 (2006) 2197-2208
3. Nezami A., Kimura T., Hidaka K., Kiso A., Liu J., Kiso Y., Goldberg D.E., and Freire E. High-affinity inhibition of a family of Plasmodium falciparum proteases by a designed adaptive inhibitor. Biochemistry 42 (2003) 8459-8464
4. Coombs G.H., Goldberg D.E., Klemba M., Berry C., Kay J., and Mottram J.C. Aspartic proteases of Plasmodium falciparum and other parasitic protozoa as drug targets. Trends Parasitol. 17 (2001) 532-537
5. Banerjee R., Liu J., Beatty W., Pelosof L., Klemba M., and Goldberg D.E. Four plasmepsins are active in the Plasmodium falciparum food vacuole, including a protease with an active-site histidine. Proc. Natl. Acad. Sci. USA 99 (2002) 990-995
6. Berry C., Humphreys M.J., Matharu P., Granger R., Horrocks P., Moon R.P., Certa U., Ridley R.G., Bur D., and Kay J. A distinct member of the aspartic proteinase gene family from the human malaria parasite Plasmodium falciparum. FEBS Lett. 447 (1999) 149-154
7. Rawlings N.D., Morton F.R., and Barrett A.J. MEROPS: the peptidase database. Nucl. Acid Res. 34 (2006) D270-D272
8. Dame J.B., Yowell C.A., Omara-Opyene L., Carlton J.M., Cooper R.A., and Li T. Plasmepsin 4, the food vacuole aspartic proteinase found in all Plasmodium spp. infecting man. Mol Biochem. Parasitol. 130 (2003) 1-12
9. Asojo, O.A., Gulnik, S., Afonina, E., Randad, R. and Silva, A. (2002) Crystal Structure of Plasmepsin IV from P. Falciparum in Complex with Pepstatin A. Protein Data Bank (http://www.rcsb.org/pdb).
10. Bernstein N.K., Cherney M.M., Yowell C.A., Dame J.B., and James M.N. Structural insights into the activation of P. vivax plasmepsin. J. Mol. Biol. 329 (2003) 505-524
11. Clemente J.C., Govindasamy L., Madabushi A., Fisher S.Z., Moose R.E., Yowell C.A., Hidaka K., Kimura T., Hayashi Y., Kiso Y., Agbandje-McKenna M., Dame J.B., Dunn B.M., and McKenna R. Structure of the aspartic protease plasmepsin 4 from the malarial parasite Plasmodium malariae bound to an allophenylnorstatine-based inhibitor. Acta Crystallogr. D 62 (2006) 246-252
12. Mimoto T., Kato R., Takaku H., Nojima S., Terashima K., Misawa S., Fukazawa T., Ueno T., Sato H., Shintani M., Kiso Y., and Hayashi H. Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine. J. Med. Chem. 42 (1999) 1789-1802
13. Nezami A., and Freire E. The integration of genomic and structural information in the development of high affinity plasmepsin inhibitors. Int. J. Parasitol. 32 (2002) 1669-1676
14. Kiso A., Hidaka K., Kimura T., Hayashi Y., Nezami A., Freire E., and Kiso Y. Search for substrate-based inhibitors fitting the S-2′ space of malarial aspartic protease plasmepsin II. J. Pept. Sci. 10 (2004) 641-647
15. DeLano Scientific. (2005) PyMOL version 0.99, San Francisco, CA.
16. Jones G., Willett P., Glen R.C., Leach A.R., and Taylor R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 267 (1997) 727-748
17. Verdonk M.L., Cole J.C., Hartshorn M.J., Murray C.W., and Taylor R.D. Improved protein-ligand docking using GOLD. Proteins 52 (2003) 609-623
18. Asojo O.A., Afonina E., Gulnik S.V., Yu B., Erickson J.W., Randad R., Medjahed D., and Silva A.M. Structures of Ser205 mutant plasmepsin II from Plasmodium falciparum at 1.8 angstrom in complex with the inhibitors rs367 and rs370. Acta Crystallogr. D 58 (2002) 2001-2008
19. Asojo O.A., Gulnik S.V., Afonina E., Yu B., Ellman J.A., Haque T.S., and Silva A.M. Novel uncomplexed and complexed structures of plasmepsin II, an aspartic protease from Plasmodium falciparum. J. Mol. Biol. 327 (2003) 173-181
20. Silva A.M., et al. Structure and inhibition of plasmepsin II, a hemoglobin-degrading enzyme from Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 93 (1996) 10034-10039
21. Åqvist J., Medina C., and Samuelsson J.E. A new method for predicting binding affinity in computer-aided drug design. Protein Eng. 7 (1994) 385-391
22. Hansson T., Marelius J., and Åqvist J. Ligand binding affinity prediction by linear interaction energy methods. J. Comput. Aided Mol. Des. 12 (1998) 27-35
23. Marelius J., Graffner-Nordberg M., Hansson T., Hallberg A., and Åqvist J. Computation of affinity and selectivity: binding of 2,4-diaminopteridine and 2,4-diaminoquinazoline inhibitors to dihydrofolate reductases. J. Comput. Aided. Mol. Des. 12 (1998) 119-131
24. Jorgensen W.L., Maxwell D.S., and TiradoRives J. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J. Am. Chem. Soc. 118 (1996) 11225-11236
25. Jorgensen W., Chandrasekhar J., Madura J., Rw I., and Klein M. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 79 (1983) 926-935
26. King G., and Warshel A. A surface constrained all-atom solvent model for effective simulations of polar solutions. J. Chem. Phys. 91 (1989) 3647-3661
27. Lee F.S., and Warshel A. A local reaction field method for fast evaluation of long-range electrostatic interactions in molecular simulations. J. Chem. Phys. 97 (1992) 3100-3107
28. Ryckaert J.P., Ciccotti G., and Berendsen H.J.C. Numerical integration of the cartesian equation of motion of a system constraints: molecular dynamics of N-alkanes. J. Comput. Phys. 23 (1977) 327-341
29. Gutiérrez-de-Terán H., Nervall M., Ersmark K., Dunn B.M., Hallberg A., and Åqvist J. Inhibitor binding to the plasmepsin IV aspartic protease from Plasmodium falciparum. Biochemistry 45 (2006) 10529-10541
30. Almlöf M., Brandsdal B.O., and Åqvist J. Binding affinity prediction with different force fields: examination of the linear interaction energy method. J. Comput. Chem. 25 (2004) 1242-1254
31. Cheng Y., and Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22 (1973) 3099-3108
32. Park H., and Lee S. Determination of the active site protonation state of β-secretase from molecular dynamics simulation and docking experiment: implications for structure-based inhibitor design. J. Am. Chem. Soc. 125 (2003) 16416-16422
33. Piana S., Sebastiani D., Carloni P., and Parrinello M. Ab initio molecular dynamics-based assignment of the protonation state of pepstatin A/HIV-1 protease cleavage site. J. Am. Chem. Soc. 123 (2001) 8730-8737
34. Polgar T., and Keseru G.M. Virtual screening for β-secretase (BACE1) inhibitors reveals the importance of protonation states at Asp32 and Asp228. J. Med. Chem. 48 (2005) 3749-3755
35. Rajamani R., and Reynolds C.H. Modeling the protonation states of the catalytic aspartates in β-secretase. J. Med. Chem. 47 (2004) 5159-5166
36. Trylska J., Grochowski P., and McCammon J.A. The role of hydrogen bonding in the enzymatic reaction catalyzed by HIV-1 protease. Protein Sci. 13 (2004) 513-528
37. Wang Y.X., Freedberg D.I., Yamazaki T., Wingfield P.T., Stahl S.J., Kaufman J.D., Kiso Y., and Torchia D.A. Solution NMR evidence that the HIV-1 protease catalytic aspartic groups have different ionization states in the complex formed with the asymmetric drug KNI-272. Biochemistry 35 (1996) 9945-9950
38. Reiling K.K., Endres N.F., Dauber D.S., Craik C.S., and Stroud R.M. Anisotropic dynamics of the JE-2147-HIV protease complex: drug resistance and thermodynamic binding mode examined in a 1.09 Å structure. Biochemistry 41 (2002) 4582-4594
39. Brynda J., et al. A phenylnorstatine inhibitor binding to HIV-1 protease: geometry, protonation, and subsite-pocket interactions analyzed at atomic resolution. J. Med. Chem. 47 (2004) 2030-2036
40. Northrop D.B. Follow the protons: a low-barrier hydrogen bond unifies the mechanisms of the aspartic proteases. Acc. Chem. Res. 34 (2001) 790-797
41. Bursavich M.G., and Rich D.H. Designing non-peptide peptidomimetics in the 21st century: inhibitors targeting conformational ensembles. J. Med. Chem. 45 (2002) 541-558
42. Brandsdal B.O., Smalås A.O., and Åqvist J. Free energy calculations show that acidic P1 variants undergo large pKa shifts upon binding to trypsin. Proteins 64 (2006) 740-748